Name: Anti-human CD3e Monoclonal Antibodies
Brand: Syd Labs
SKU: PA007387.m2a
Price: 150.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007387.m2a

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: 12F6), Mouse IgG2a Kappa

1 mg

150.00

PA007387.m2a

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: 12F6), Mouse IgG2a Kappa

5 mg

350.00

PA007387.m2a

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: 12F6), Mouse IgG2a Kappa

25 mg

900.00

Description

PA007387.m2a: In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Mouse IgG2a Kappa (Clone: 12F6)

Recombinant mouse IgG2a Monoclonal Antibody.
Clone: 12F6.
Isotype: Mouse IgG2a kappa.
Source: The anti-human CD3e monoclonal antibody (clone: 12F6) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 12F6) specifically binds to human CD3e.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD3e protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The 12F6 antibody competes with the OKT3 antibody for binding to human T cells, and has more effective T-cell suppression and activation properties than OKT3. The 12F6 antibody is used to study T-cell functions and to manipulate T-cell activation and suppression, prevent acute allograft rejection, and treat autoimmune diabetes.

References of anti-human CD3e antibody (12F6)

Bispecific antibodies cross-link and redirect CD8+ T cells to kill cytomegalovirus-infected cells
Ali, A., et al. (2024). Sci Adv. 10(9):eady2092. doi: 10.1126/sciadv.ady2092. PMID: 38442054
A bispecific antibody utilizing the anti-CD3 antibody (clone 12F6) was constructed to engage T cells in NOD/SCID mice infected with CMV. In vivo studies demonstrated a significant reduction in viral load in treated mice. Flow cytometry confirmed CD8+ T cell activation in spleen and liver tissues, showing enhanced T cell-mediated cytotoxicity against CMV-infected cells. Control groups receiving isotype antibodies exhibited no significant viral clearance.
Tags: anti-human CD3e 12F6; anti-human CD3e 12F6 in vivo

Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells
Li, J., et al. (2009). Immunol Lett. 125(2):75-84. doi: 10.1016/j.imlet.2009.04.002. PMID: 19410632
The humanized anti-CD3 antibody (12F6) was administered to humanized mice to evaluate its immunoregulatory effects. Treatment with 12F6 significantly reduced T cell proliferation in peripheral blood and increased IL-10 while decreasing IFN-γ levels, as shown by cytokine analysis. Flow cytometry on blood samples confirmed in vivo T cell depletion, demonstrating that 12F6 (anti-human CD3e antibody) induces a regulatory T cell phenotype.
Tags: anti-human CD3e 12F6 antibody in vivo; anti-human CD3e 12F6 in animal model

Phase I trial of a humanized, Fc receptor nonbinding anti-CD3 antibody, hu12F6mu in patients receiving renal allografts
Sandborn, W. J., et al. (2010). MAbs. 2(4):444-55. doi: 10.4161/mabs.2.4.12305. PMID: 20564327
The hu12F6mu antibody, a humanized version of the 12F6 antibody (anti-human CD3e antibody), was administered to renal allograft patients to prevent rejection. Flow cytometry confirmed reduced CD3+ T cell counts in peripheral blood within 48 hours. The trial assessed the safety profile of hu12F6mu in a dose-escalation study, with no significant cytokine release syndrome reported in the low-dose cohort.
Tags: anti-human CD3e 12F6 in cancer research; anti-human CD3e 12F6

Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions
Li, B., et al. (2005). Immunology. 116(4):487-98. doi: 10.1111/j.1365-2567.2005.02249.x. PMID: 16014509
A humanized anti-CD3 monoclonal antibody (12F6) was tested in NOD/SCID mice reconstituted with human PBMCs. The 12F6 antibody (anti-human CD3e antibody) effectively suppressed T cell-mediated graft-versus-host disease in vivo. Flow cytometry showed a significant reduction in CD3+ T cells in spleen samples and a shift toward regulatory T cell populations, with no significant cytokine release observed.
Tags: function of anti-human CD3e 12F6 antibody; bioactivity of anti-human CD3e 12F6

Humanization of the murine anti-human CD3 monoclonal antibody OKT3
Adair, J. R., et al. (1994). Hum Antibodies Hybridomas. 5(1-2):41-7. PMID: 8006592
The 12F6 antibody (anti-human CD3e antibody) was used as a comparator to assess the efficacy of humanized OKT3 in a humanized mouse model. Both humanized OKT3 and 12F6 were administered to evaluate T cell suppression, showing comparable CD3+ T cell depletion via flow cytometry. In vivo experiments demonstrated reduced graft rejection in treated animals, confirming the immunosuppressive properties of both antibodies.
Tags: anti-human CD3e antibody (12F6); anti-CD3e clone 12F6